# Early and Low Dose Deferasirox (3.5 mg/kg FCT) to Suppress NTBI and LPI as Early Intervention to Prevent Tissue Iron Overload in Lower Risk MDS

> **NCT03920657** · PHASE2 · TERMINATED · sponsor: **Fondazione Italiana Sindromi Mielodisplastiche-ETS** · enrollment: 11 (actual)

## Conditions studied

- Myelodysplastic Syndromes

## Interventions

- **DRUG:** Deferasirox

## Key facts

- **NCT ID:** NCT03920657
- **Lead sponsor:** Fondazione Italiana Sindromi Mielodisplastiche-ETS
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-10-04
- **Primary completion:** 2020-10-06
- **Final completion:** 2022-04-22
- **Target enrollment:** 11 (ACTUAL)
- **Why stopped:** enrollment failed
- **Last updated:** 2022-11-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03920657

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03920657, "Early and Low Dose Deferasirox (3.5 mg/kg FCT) to Suppress NTBI and LPI as Early Intervention to Prevent Tissue Iron Overload in Lower Risk MDS". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT03920657. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*